Abstracts tagged "Women’s health"

Abstract Number: 1985 • ACR Convergence 2025
Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Rachel Galvao, Anokhi Saklecha, Julia Stevenson, Ritche Hao, Eugenia Chock and Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Teratogenic medications are commonly prescribed to women of reproductive age who have rheumatic conditions. Counseling on teratogenicity and contraception is critical to reducing patients’…
Abstract Number: 2217 • ACR Convergence 2025
Improving Patient Counseling on Medication Safety During Reproductive Years
Lauren He¹, Anne Carlton², Rocio Bautista-Sanchez¹, Yasmin Khader³ and Puja Khanna⁴, ¹University of Michigan, Ann Arbor, ²University of Michigan, Ann Arbor, MI, ³University of Michigan/VA Ann Arbor, Ann Arbor, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with rheumatic diseases require dedicated counseling on reproductive planning from their rheumatologist.1 Information shared on safety of medications during pregnancy and lactation can…
Abstract Number: 1972 • ACR Convergence 2025
Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic
Abimbola Fadairo-Azinge¹, jobelle Romulo², Daniella Flores³, jose Giron², Joshua Ng⁴, Sarah Patterson⁵, Jinoos Yazdany⁶ and Andrew Gross⁶, ¹UCSF, San Francisco, ²University of California San Francisco, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, SAN-FRANCISCO, CA, ⁵University of California, San Francisco, Pacifica, CA, ⁶UCSF, San Francisco, CA
Background/Purpose: The American College of Rheumatology (ACR) recommends contraceptive counseling for reproductive-age women with rheumatic and musculoskeletal diseases (RMDs), especially those on teratogenic medications. These…
Abstract Number: 2218 • ACR Convergence 2025
Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study
Edgar Iván Mendoza Ríos, María Del Carmen Zamora Medina, Mario Isaac Lumbreras Márquez, Diana Yazmin Copado mendoza, Oralia Alejandra Orozco Guillén, Maria José rodríguez Sibaja, Martha Leticia Palafox Vargas and Sandra Acevedo gallegos, Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: IgA vasculitis (IgA-V) is a systemic vasculitis involving small vessels, most frequently affecting children. There is few information about pregnancy outcomes in women with…
Abstract Number: 1635 • ACR Convergence 2025
Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases
Daniela L. Guillen-Tejada¹, Aura Matilde Jiménez-Garduño¹ and Montserrat Lamuño Encorrada², ¹Universidad de las Américas Puebla, Puebla, Mexico, ²Hospital Ángeles Puebla, Puebla, Mexico
Background/Purpose: Management of rheumatic diseases relies on chronic treatment, often with a greater risk of nonadherence. Frailty is characterized by decreased physiological function that increases patients’…
Abstract Number: 2216 • ACR Convergence 2025
Expanding Reproductive Health Assessments in Rheumatic Diseases: A Comparative Analysis of Demographic and Disease-Specific Factors
Krista Topalsky¹, Chelsea Guan², Lindsay Frumker³, Dana Nachawati², Areeb Tiwana⁴, Meghan Gump², Omer Pamuk⁵ and Marina Magrey⁶, ¹University Hospitals, Shaker Heights, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH, ⁴Canton Medical Education Foundation, Canton, OH, ⁵University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Building on our 2024 ACR study (Topalsky et al.) that described broad knowledge gaps and interest in reproductive health education among women with rheumatic…
Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Ranjan Gupta, Nilanchali Singh, Nisha Jawaliya, Rudra Prosad Goswami, Soniya Dhiman and Parul baisoya, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…
Abstract Number: 2660 • ACR Convergence 2025
Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
Shreya Billa¹, Sho Fukui¹, Misti Paudel², Takahiro Suzuki³, Ryosuke Imai⁴, Yuntae Kim⁵, Takehiro Nakai⁶, Hiromichi Tamaki⁶, mitsumasa kishimoto⁷, Hilde Ørbo¹, Sara Tedeschi¹, Hyon K. Choi⁸, Masato Okada⁹ and Daniel Solomon¹, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Department of Cardiovascular Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Gastroenterology, St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁷Kyorin University School of Medicine, Tokyo, Japan, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Understanding longitudinal changes in serum urate (SU) allows for the development of evidence-based interventions for gout. Post-menopausal women, who are at risk of gout,…
Abstract Number: 2215 • ACR Convergence 2025
Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
Kaitlin Nuechterlein¹, Karl Grenier¹, Luisa Ciofani², Kalliopi Panaritis², Sasha Bernatsky² and Evelyne Vinet², ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Placenta-mediated adverse pregnancy outcomes (APO) are a huge concern in SLE. Recent efforts to understand APO include the establishment of the 2016 Amsterdam classification…
Abstract Number: 1492 • ACR Convergence 2025
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
Katherine Moseley¹, Dulaney Wilson², Emily Vara¹ and Diane Kamen³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder that is nine times more prevalent in women. Patients with SLE are at an…
Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Rachael Stovall¹, Cinthia Blat², Eric Roberts³, Jean Liew⁴, Katherine Wysham⁵, Namrata Singh¹, Janna Friedly¹, Lianne S. Gensler⁶, gabriela Schmajuk⁷ and Jinoos Yazdany⁸, ¹University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, SF, CA, ⁴Boston University School of Medicine, Boston, MA, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁸UCSF, San Francisco, CA
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…
Abstract Number: 2213 • ACR Convergence 2025
Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases
Juhi Dixit, Shri Balaji Institute of Medical Sciences, Mowa Raipur, Raipur, Chhattisgarh, India
Background/Purpose: This study aims to find out knowledge, attitude, practices and beliefs of patients with autoimmune rheumatic diseases regarding family planning, contraception, drug use and…
Abstract Number: 1070 • ACR Convergence 2025
Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
Mahnoor Javed¹, Deepak Jagannath², Alma Aveytia Camacho³, Alwyn Mathew³, Konrad Harms³, Soudabeh Daliri³ and Myriam Guevara⁴, ¹Houston Methodist, Richmond, TX, ²Houston Methodist Hospital, Sugar Land, TX, ³Houston Methodist, Houston, ⁴Houston Methodist, Houston, TX
Background/Purpose: Women with SLE are at an increased risk of developing cervical cancer, primarily by human papillomavirus (HPV) and immunosuppression. This elevated risk has been…
Abstract Number: 0420 • ACR Convergence 2024
Factors Associated with Infant Feeding Behaviors Among Women with Systemic Rheumatic Diseases
Sarah Lieber¹, Lucy Masto¹, Amaya Smole², Ranqing Lan¹, Michael Parides¹, Jonah Levine¹, Bessie Stamm¹, Caroline Siegel¹, Lisa Mandl¹, Michael Lockshin³, Medha Barbhaiya¹ and Lisa Sammaritano⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Brooklyn, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Scarsdale, NY
Background/Purpose: Although guidelines support acceptability of breastfeeding (BF)/pumping in women with systemic rheumatic diseases (SRDs) when taking BF-compatible medications, little is known about factors influencing…
Abstract Number: 0447 • ACR Convergence 2024
Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Connie Lin¹, Anja Geldhof², Mauricio Ballina³, Hetal Patel⁴ and Hewei Li⁵, ¹Janssen R&D US, Horsham, PA, ²Director Postmarketing Commitments, Leiden, Netherlands, ³Actelion Research & Development, Basel, Switzerland, Gewerbestrasse, Basel-Landschaft, Switzerland, ⁴Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, ⁵Janssen Pharmaceutical, Hopewell Township, NJ
Background/Purpose: Data pertaining to the use of biologics in immunologic diseases are limited on their use during pregnancy. Guselkumab (GUS) is a human IgG1λ mAb…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].